EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Maravai LifeSciences Holdings EBITDA Margin % Related Terms
Maravai LifeSciences Holdings EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:MRVI vs ANRO, BBOT, REPL: EBITDA Margin % Comparison
For the Biotechnology subindustry, Maravai LifeSciences Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maravai LifeSciences Holdings EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Maravai LifeSciences Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Maravai LifeSciences Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maravai LifeSciences Holdings (MEX:MRVI) has a EBITDA Margin % of 18.53% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Maravai LifeSciences Holdings and its competitors. This is 55% below median its historical median of 41.17. According to the industry distribution chart, Maravai LifeSciences Holdings ranks #452 out of 944 companies in the Biotechnology industry, placing it in the top 47.9%.
Is Maravai LifeSciences Holdings' EBITDA Margin % too high?
Maravai LifeSciences Holdings' current EBITDA Margin % of 18.53% is 55% below median its 10-year median of 41.17. Based on the distribution chart, Maravai LifeSciences Holdings ranks #452 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Maravai LifeSciences Holdings has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Maravai LifeSciences Holdings' EBITDA Margin % compare to ANRO and BBOT?
According to the Biotechnology industry distribution chart, Maravai LifeSciences Holdings ranks #452 out of 944 companies for EBITDA Margin %. This puts Maravai LifeSciences Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Maravai LifeSciences Holdings and its competitors. Maravai LifeSciences Holdings's current EBITDA Margin % is 18.53%, which is 55% below median its own 10-year median of 41.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maravai LifeSciences Holdings stock overvalued right now?
Maravai LifeSciences Holdings (MEX:MRVI) has a current EBITDA Margin % of 18.53%. The stock's GF Value™ is MXN53.06, compared to a current price of MXN85.00 — trading 60.2% above its estimated fair value. The current EBITDA Margin % is 18.53%, which is 55% below median its 10-year median of 41.17. Maravai LifeSciences Holdings' overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Maravai LifeSciences Holdings (MEX:MRVI), the current EBITDA Margin % is 18.53% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maravai LifeSciences Holdings (MEX:MRVI) Overvalued in 2026?
Based on GuruFocus' analysis, Maravai LifeSciences Holdings stock appears to be overvalued.
The current stock price of MXN85.00 is trading 60.2% above its estimated GF Value™ of MXN53.06.
Key valuation signals for MEX:MRVI:
EBITDA Margin %: 18.53% (55% below median its 10-year median of 41.17)
GF Value™: MXN53.06 vs. price of MXN85.00 (60.2% above fair value)
No single metric tells the full story. See the MEX:MRVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maravai LifeSciences Holdings Business Description
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
62GF Score
Get the complete analysis for MEX:MRVI
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MRVI has been successfully added to your 
